Lv1
65 积分 2020-10-01 加入
Updated results from ALTER-S002: A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with stage IIB classic osteosarcoma of the extremity
1个月前
已完结
Efficacy and safety of perioperative anlotinib combined with cisplatin and doxorubicin in treatment-naive stage IIB classic osteosarcoma of the extremity: Updated results from the ALTER-S002 trial
1个月前
已关闭
Learnings from Approved Antibody‐Drug Conjugates: Clinical Pharmacology Perspectives
2个月前
已完结
Giredestrant Delivers Long-Sought Adjuvant Benefit
4个月前
已完结
Abstract GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial
4个月前
已关闭
The discovery of novel sanjuanolide derivatives as chemotherapeutic agents targeting castration-resistant prostate cancer
6个月前
已完结
The discovery of novel sanjuanolide derivatives as chemotherapeutic agents targeting castration-resistant prostate cancer
7个月前
已完结
Synthesis and biological evaluation of novel N-substituted benzamides as anti-migration agents for treatment of osteosarcoma
7个月前
已完结
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study
11个月前
已完结
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
11个月前
已完结
皖公网安备34019202002308
